Bio-Path Holdings (BPTH) Stock Overview

Operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. More details

BPTH fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Rewards

Earnings have grown 7.4% per year over the past 5 years

Risk Analysis

Makes less than USD$1m in revenue ($0)

Negative shareholders equity

Shareholders have been substantially diluted in the past year

Has less than 1 year of cash runway

+ 2 more risks

BPTH Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW428,308 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

428,308 investors already sharing narratives

View all narratives

Bio-Path Holdings, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Bio-Path Holdings
Historical stock prices
Current Share Price	US$0.0002
52 Week High	US$0.11
52 Week Low	US$0.0001
Beta	-0.53
1 Month Change	-99.44%
3 Month Change	-99.46%
1 Year Change	-99.65%
3 Year Change	-99.90%
5 Year Change	-99.90%
Change since IPO	-99.90%

Recent updates

Analysis Article • Nov 05

We're Keeping An Eye On Bio-Path Holdings' (NASDAQ:BPTH) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Seeking Alpha • Aug 16

Bio-Path GAAP EPS of -$0.42 beats by $0.07

Bio-Path press release (NASDAQ:BPTH): Q2 GAAP EPS of -$0.42 beats by $0.07. As of June 30, 2022, the Company had cash of $17.0 million, compared to $23.8 million at December 31, 2021.

Analysis Article • Jul 08

Is Bio-Path Holdings (NASDAQ:BPTH) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Analysis Article • Mar 24

Here's Why We're Not Too Worried About Bio-Path Holdings' (NASDAQ:BPTH) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Analysis Article • Aug 17

Bio-Path Holdings (NASDAQ:BPTH) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Analysis Article • Mar 26

We Think Bio-Path Holdings (NASDAQ:BPTH) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Shareholder Returns

	BPTH	US Biotechs	US Market
7D	100.0%	0.4%	-0.2%
1Y	-99.6%	36.4%	11.9%

Return vs Industry: BPTH underperformed the US Biotechs industry which returned 37.1% over the past year.

Return vs Market: BPTH underperformed the US Market which returned 12% over the past year.

Price Volatility

Is BPTH's price volatile compared to industry and market?
BPTH volatility
BPTH Average Weekly Movement	61.2%
Biotechs Industry Average Movement	9.5%
Market Average Movement	6.8%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	2.9%

Stable Share Price: BPTH's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: BPTH's weekly volatility has increased from 37% to 61% over the past year.

About the Company

Founded	Employees	CEO	Website
2007	1	Vik Grover	www.biopathholdings.com

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. Its drug delivery and antisense technology is the DNAbilize, a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body’s enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge. The company’s lead drug candidate is the Prexigebersen (BP1001), which is in phase 2 clinical trial for the treatment of untreated acute myeloid leukemia (AML).

Bio-Path Holdings, Inc. Fundamentals Summary

How do Bio-Path Holdings's earnings and revenue compare to its market cap?
BPTH fundamental statistics
Market cap	US$5.03k
Earnings (TTM)	-US$4.13m
Revenue (TTM)	n/a

0.0x

P/S Ratio

0.0x

P/E Ratio

Is BPTH overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BPTH income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$4.13m
Earnings	-US$4.13m

Last Reported Earnings

Jun 30, 2026

Next Earnings Date

n/a

Earnings per share (EPS)	-0.082
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	-5.4%

How did BPTH perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/09/18 23:48
End of Day Share Price	2026/09/18 00:00
Earnings	2026/06/30
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Bio-Path Holdings, Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Jason Kolbert	Maxim Group
Pamela Bassett	Maxim Group

Bio-Path Holdings (BPTH) Stock Overview

Rewards

Risk Analysis

Join community and earn perks

Bio-Path Holdings, Inc. Competitors

Vincerx Pharma

ProtoKinetix

Lipella Pharmaceuticals

Synairgen

Price History & Performance

Recent News & Updates

Bio-Path Holdings, Inc. announced delayed 10-Q filing

Bio-Path Holdings, Inc. announced delayed 10-Q filing

Nasdaq to Delist Common Stock of Bio-Path Holdings

Bio-Path Holdings, Inc. Provides Clinical and Operational Update

Bio-Path Holdings, Inc. Achieves Third Pre-Clinical Milestone Confirming Potential of Bp1001-A as Treatment for Obesity in Type 2 Diabetes Patients

Bio-Path Holdings, Inc. has filed a Follow-on Equity Offering.

Recent updates

Bio-Path Holdings, Inc. announced delayed 10-Q filing

Bio-Path Holdings, Inc. announced delayed 10-Q filing

Nasdaq to Delist Common Stock of Bio-Path Holdings

Bio-Path Holdings, Inc. Provides Clinical and Operational Update

Bio-Path Holdings, Inc. Achieves Third Pre-Clinical Milestone Confirming Potential of Bp1001-A as Treatment for Obesity in Type 2 Diabetes Patients

Bio-Path Holdings, Inc. has filed a Follow-on Equity Offering.

Bio-Path Holdings, Inc. has withdrawn its Follow-on Equity Offering in the amount of $10 million.

Bio-Path Holdings, Inc. announced that it expects to receive $0.1005 million in funding from 1800 Diagonal Lending, LLC

Bio-Path Holdings Announces Pre-Clinical Results Signaling Increased Potential for BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients

Bio-Path Holdings, Inc. announced that it has received $0.14 million in funding from 1800 Diagonal Lending, LLC

Bio-Path Holdings, Inc.(OTCPK:BPTH) dropped from S&P TMI Index

Bio-Path Holdings, Inc.(OTCPK:BPTH) dropped from NASDAQ Composite Index

Bio-Path Holdings, Inc. Provides an Update from It's Ongoing Phase 1/1B Clinical Trial of BP1001-A in Solid Tumor Patients and Reports Continued Patient Progress from it's Ongoing Phase 2 Triple Combination Study of Prexigebersen in Acute Myeloid Leukemia

Bio-Path Holdings, Inc. Provides Update from Phase 1/1b Clinical Trial of BP1002 for Treatment of Refractory/Relapsed Acute Myeloid Leukemia

Bio-Path Holdings, Inc. Announces Preclinical Testing of Bp1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients Enhances Insulin Sensitivity

Bio-Path Holdings Receives Non-Compliance Letter Regarding Nasdaq Listing Rule 5550(a)(2)

Bio-Path Holdings, Inc. Announces Plans to Discontinue Its Phase 1 Clinical Trial Evaluating Bp10012 as A Treatment for Obesity and Relapsed/Refractory Chronic Lymphocytic Leukemia Due to Enrollment Challenges in Niche Patient Populations

New major risk - Negative shareholders equity

Bio-Path Holdings, Inc. to Report Q3, 2024 Results on Nov 15, 2024

Bio-Path Holdings, Inc., Annual General Meeting, Dec 12, 2024

Bio-Path Holdings, Inc. announced that it expects to receive $4.000001 million in funding

Bio-Path Holdings, Inc. Initiates Development of Therapeutic Program for Treatment of Obesity

Bio-Path Holdings Receives Non-Compliance Letter from Nasdaq Regarding Minimum Stockholders’ Equity Requirement

Bio-Path Holdings, Inc. Reports Solid Tumor Patient Response Supporting BP1001-A's Compelling Potential as Treatment for Advanced Solid Tumors

New major risk - Financial position

Bio-Path Holdings, Inc. to Report Q2, 2024 Results on Aug 15, 2024

Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia At European Hematology Association Congress

Bio-Path Holdings, Inc. announced that it expects to receive $4.000001 million in funding

New major risk - Negative shareholders equity

Bio-Path Holdings, Inc. to Report Q1, 2024 Results on May 15, 2024

Bio-Path Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $1.209375 million.

New major risk - Share price stability

Bio-Path Holdings, Inc. Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1B Clinical Trial of Bp1002 in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients

Bio-Path Holdings, Inc. Expands Global Patent Portfolio

Bio-Path Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $2 million.

New minor risk - Profitability

Bio-Path Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $0.29925 million.

Bio-Path Holdings, Inc. has withdrawn its Follow-on Equity Offering in the amount of $7.499995 million.

Bio-Path Holdings Receives Deficiency Letter from the Listing Qualifications Department of the Nasdaq Regarding Listing Rule 5550(b)(1)

Bio-Path Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $7.499995 million.

Bio-Path Holdings, Inc. to Report Q4, 2023 Results on Mar 08, 2024

Bio-Path Holdings, Inc. has withdrawn its Follow-on Equity Offering in the amount of $23.75 million.

New major risk - Share price stability

Bio-Path Holdings Announces Completion of First Dose Cohort in Phase 1 Clinical Trial Evaluating BP1002 to Treat Refractory/Relapsed Lymphoma and Refractory/Relapsed Chronic Lymphocytic Leukemia Patients

Bio-Path Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $19 million.

Bio-Path Holdings Successfully Completes First Dose Cohort of Phase 1/1B Clinical Trial of Bp1002 in Refractory/Relapsed Acute Myeloid Leukemia

No longer forecast to breakeven

Bio-Path Holdings, Inc. to Report Q3, 2023 Results on Nov 15, 2023

Bio-Path Holdings, Inc., Annual General Meeting, Dec 14, 2023

Bio-Path Holdings, Inc. Receives Non-Compliance Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Price target decreased by 7.7% to US$12.00

Bio-Path Holdings, Inc. to Report Q2, 2023 Results on Aug 15, 2023

New major risk - Shareholder dilution

New major risk - Share price stability

Bio-Path Holdings, Inc. Announces Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia

New major risk - Market cap size

New minor risk - Share price stability

Bio-Path Holdings, Inc. to Report Q1, 2023 Results on May 12, 2023

Forecast to breakeven in 2025

Bio-Path Holdings, Inc. Announces First Patient Dosed in Phase 1/1b Clinical Trial of BP1001-A in Solid Tumors

Price target decreased to US$11.00

Bio-Path Holdings, Inc. to Report Q3, 2022 Results on Nov 15, 2022